Long covid medication and method of treatment
OwnerEllen Kirschnerinventor
Life of this patent
Estimating the term…
Loading patent…
OwnerEllen Kirschnerinventor
Estimating the term…
Compositions and methods of use for treatment of Long Covid, or other post-viral or other post-infection conditions that result in a toxin induced thickened blood pulp condition (e.g., including but not limited to influenza, zika, herpes, or epstein-barr viruses). The treatment composition includes C29H40N2O4; C9H2N2; and/or C28H38N2O4; and optionally a source of iron. A filler (e.g., CaCO3) or pharmaceutically acceptable carrier may be provided. In the treatment method, treatment composition is administered to a patient, specifically because of the patient's exhibition of symptoms of Long Covid (or other contemplated post-viral or other post-infection condition). The treatment composition can be administered as a single dose. The components thereof have a molecular and/or particle size sufficiently small so as to not induce vomiting, and the single dose administration to the patient is sufficient so that the patient's Long Covid symptoms are relieved within a period of about 10 days.
A composition for use in treatment of Long Covid, or other post-viral or other post-infection conditions that result in a toxin induced thickened blood pulp condition, the composition comprising:
A method for treatment of Long Covid, or other post-viral or other post-infection conditions that result in a toxin induced thickened blood pulp condition, the method comprising:
A method for treatment of Long Covid, the method comprising:
Use of a treatment composition in a drug or other treatment composition, for treatment of Long Covid, other post-viral, or other post-infection conditions, wherein the composition comprises:
Use of a treatment composition to interfere with the metabolism of COVID-19 or other viruses, wherein the composition comprises:
Dependencies are inferred from the claim text.